VONTOBEL FINANCIAL PRODUCTS GMBH | Market Closed - Boerse Frankfurt Warrants 14:05:18 2024-05-31 EDT | ||
| 101.9 EUR | -.--% |
|
| Current month | +0.14% | ||
| 1 month | +0.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 101.9 | -.--% |
| 24-05-30 | 101.9 | +0.06% |
| 24-05-29 | 101.8 | -.--% |
| 24-05-28 | 101.8 | +0.05% |
| 24-05-27 | 101.8 | -0.15% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 02:05 pm
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM7ECJ |
| ISIN | DE000VM7ECJ2 |
| Date issued | 2024-01-22 |
| Strike | 726.6 kr |
| Maturity | 2024-12-20 (202 Days) |
| Parity | 0.73 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 102.5 € |
|---|---|
| Lowest since issue | 98.67 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
